Advertisement

International Journal of Hematology

, Volume 75, Issue 2, pp 191–194 | Cite as

Bone Marrow Cytogenetic Complete Remission Achieved by Interferon-α Plus Cytarabine Ocfosfate Therapy in a Patient With Chronic Myelogenous Leukemia During Extramedullary Blast Crisis

  • Akihiko Gotoh
  • Keisuke Miyazawa
  • Yoshiko Uchida
  • Goro Sashida
  • Ken Kawakubo
  • Yuzuru Kuriyama
  • Kazuma Ohyashiki
Case Report

Abstract

We report a case of chronic myelogenous leukemia (CML) in which the bone marrow achieved cytogenetic complete remission (CCR) achieved by treatment with interferon-α and oral cytarabine ocfosfate after extramedullary blast crisis. A 51-year-old Japanese man diagnosed with CML was treated with interferon-α. Two months later; lymph node swellings developed in his neck and inguinal regions. Lymph node biopsy revealed the infiltration of blast cells showingbcr-abl fusion signal by fluorescence in situ hybridization analysis. Bone marrow aspiration and cytogenetic analysis demonstrated that his bone marrow was still in the chronic phase, with minor cytogenetic response. Continuing interferon-α for 6 months in combination with oral cytarabine ocfosfate resulted in the disappearance of the neck lymph node swellings followed by CCR in the bone marrow. However, rapid reenlargement of the neck and inguinal lymph nodes was noted 2 months after CCR despite maintaining medullary remission with major cytogenetic response. Finally, medullary crisis was noted 13 months from the initial development of the extramedullary crisis. This case suggests that interferon-a plus cytarabine ocfosfate therapy may be of benefit in the treatment of extramedullary blast crisis of CML.

Key words

Chromic myelogenous leukemia Extramedullary blast crisis Cytogenetic remission Interferon α Cytarabine ocfosfate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referencess

  1. 1.
    The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.N Engl J Med. 1994;330:820–825.CrossRefGoogle Scholar
  2. 2.
    Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Montserrat E, Rozman C. A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia.Br J Haematol. 1990;76:27–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Terjanian T, Kantarjian H, Keating M, Talpaz M, McCredie K, Freireich EJ. Clinical and prognostic features of patients with Philadelphia chromosome-positive chronic myelogenous leukemia and extramedullary disease.Cancer. 1987;59:297–300.CrossRefPubMedGoogle Scholar
  4. 4.
    O’Brien S, Witt R, Talpaz M, Kantarjian H. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.Cancer. 1991;67:1946–1949.CrossRefPubMedGoogle Scholar
  5. 5.
    Beedassy A, Topolsky D, Styler M, Crilley P. Extramedullary blast crisis in a patient with chromic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-a therapy.Leukemia Res. 2000;24:733–735.CrossRefGoogle Scholar
  6. 6.
    Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia.Blood. 1984;63:789–799.PubMedGoogle Scholar
  7. 7.
    Gotoh A, Broxmeyer HE. The function of BCR/ABL and related proto-oncogenes.Curr Opin Hematol. 1997;4:3–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Kantarjian HM, O’Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.J Clin Oncol. 1999;17:284.CrossRefPubMedGoogle Scholar
  9. 9.
    Alimena G, Lazzarino M, Morra E, et al. Clinical and cyotologic characteristics of blastic phase in Ph-positive chronic myeloid leukemia treated with interferon-a.Leukemia. 1996;10:615–618.PubMedGoogle Scholar
  10. 10.
    Specchia G, Palumbo G, Pastore D, Mininni D, Mestice A. Liso V. Extramedullary blast crisis in chronic myeloid leukemia.Leukemia Res. 1996;20:905–908.CrossRefGoogle Scholar
  11. 11.
    Goto H, Tsurumi H, Hara T, Moriwaki H. Lymphoid blast crisis during interferon-a therapy in a patient with chronic myelogenous leukemia in myeloid blast crisis.Int J Hematol. 2000;72:474–476.PubMedGoogle Scholar
  12. 12.
    Iwamasa K, Yasukawa M, Fujita S. A case of chronic myelogenous leukemia with T lymphoblastic and megakaryoblastic mixed crisis.Jpn J Med. 1989;28:89–95.CrossRefPubMedGoogle Scholar
  13. 13.
    Honda H, Miyagawa K, Endo M, Takaku F, Hirai H. Disappearance of Ph1 chromosome with intensive chemotherapy and detection of minimal residual disease by polymerase chain reaction in a patient with blast crisis of chronic myelogenous leukemia.Int J Hematol. 1993;57:221–227.PubMedGoogle Scholar
  14. 14.
    Marasca R, Longo G, Lui M, Barozzi P. Torelli G Double P53 point mutation in extramedullary blast crisis of chronic myelogenous leukemia.Leukemia Lymphoma. 1994;16:171–175.CrossRefPubMedGoogle Scholar
  15. 15.
    Marasca R, Lpi M, Barozzi P, Ferrari MG, Morselli M. Torelli G P53 gene mutations in chronic myelogenous leukemia medullary and extramedullary blast crisis.Leukemia Lymphoma. 1996;24:175–182.CrossRefPubMedGoogle Scholar
  16. 16.
    Santin AD. Lymph node metastasis: the importance of the microenvironment.Cancer. 2000;88:175–179.CrossRefPubMedGoogle Scholar
  17. 17.
    McGlave P, Verfaillie C, Miller J. Interaction of primitive human myeloid and lymphoid progenitors with the marrow environment.Blood Cells. 1994;20:121–126.PubMedGoogle Scholar
  18. 18.
    Bradstock KF, Gottlieb DJ. Interaction of leukemia cells with the bone marrow microenvironment.Leukemia Lymphoma. 1995;18:1–16.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Akihiko Gotoh
    • 1
  • Keisuke Miyazawa
    • 1
  • Yoshiko Uchida
    • 1
  • Goro Sashida
    • 1
  • Ken Kawakubo
    • 1
  • Yuzuru Kuriyama
    • 1
  • Kazuma Ohyashiki
    • 1
  1. 1.First Department of Internal MedicineTokyo Medical UniversityTokyoJapan

Personalised recommendations